Iron(III)-Salophene: An Organometallic Compound with Selective Cytotoxic and Anti-Proliferative Properties in Platinum-Resistant Ovarian Cancer Cells by Lange, Thilo S. et al.
Iron(III)-Salophene: An Organometallic Compound with
Selective Cytotoxic and Anti-Proliferative Properties in
Platinum-Resistant Ovarian Cancer Cells
Thilo S. Lange
1,2., Kyu Kwang Kim
1., Rakesh K. Singh
1, Robert M. Strongin
3, Carolyn K. McCourt
1,
Laurent Brard
1*
1Molecular Therapeutics Laboratory, Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants’ Hospital of RI, Warren Alpert
Medical School of Brown University, Providence, Rhode Island, United States of America, 2Department of Biology and Medicine, Brown University, Providence, Rhode
Island, United States of America, 3Department of Chemistry, Portland State University, Portland, Oregon, United States of America
Abstract
Background: In this pioneer study to the biological activity of organometallic compound Iron(III)-salophene (Fe-SP) the
specific effects of Fe-SP on viability, morphology, proliferation, and cell-cycle progression on platinum-resistant ovarian
cancer cell lines were investigated.
Methodology/Principal Findings: Fe-SP displayed selective cytotoxicity against SKOV-3 and OVCAR-3 (ovarian epithelial
adenocarcinoma) cell lines at concentrations between 100 nM and 1 mM, while the viability of HeLa cells (epithelial cervix
adenocarcinoma) or primary lung or skin fibroblasts was not affected. SKOV-3 cells in contrast to fibroblasts after treatment
with Fe-SP revealed apparent hallmarks of apoptosis including densely stained nuclear granular bodies within fragmented
nuclei, highly condensed chromatin and chromatin fragmentation. Fe-SP treatment led to the activation of markers of the
extrinsic (Caspase-8) and intrinsic (Caspase-9) pathway of apoptosis as well as of executioner Caspase-3 while PARP-1 was
deactivated. Fe-SP exerted effects as an anti-proliferative agent with an IC50 value of 300 nM and caused delayed
progression of cells through S-phase phase of the cell cycle resulting in a complete S-phase arrest. When intra-peritoneally
applied to rats Fe-SP did not show any systemic toxicity at concentrations that in preliminary trials were determined to be
chemotherapeutic relevant doses in a rat ovarian cancer cell model.
Conclusion/Significance: The present report suggests that Fe-SP is a potent growth-suppressing agent in vitro for cell lines
derived from ovarian cancer and a potential therapeutic drug to treat such tumors in vivo.
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Introduction
Minerals and metals have been employed in various forms of
medical treatment for several thousand years. In ancient Egypt
and Greece, in Ayurvedic medicine, asian medicine, or by the
Aztecs metals in elementary form, as salts or as pharmaceutically
active compounds from plants were used mainly due to anti-
inflammatory effects associated with the application [1,2]. Metals
found their revival in pharmacological efforts during the
renaissance [2], however, often with toxic side-effects due to
heavy metal use. The earliest report on the therapeutic use of
metals or metal containing compounds not only as before in
ulcerous conditions but in cancer and leukemia date back to the
sixteenth century [3,4]. Several recent reviews have described the
characteristics of diverse metal compounds and their use and/or
putative mode of action in modern cancer treatment in pre-clinical
and clinical studies [4,5,6].
The current treatment of a variety of tumors, including ovarian
cancer, relies on organometallic platinum compounds. In the
United States, epithelial ovarian cancer (EOC) is the leading cause
of death from gynecologic malignancies and the fourth most
common cause of death due to cancer among women [7]. An
estimated twenty-two thousand new cases and an estimated fifteen-
thousand deaths secondary to ovarian cancer occurred in the year
2007 [8]. Although most patients initially respond to cytoreductive
surgery and adjuvant paclitaxel and platinum-based chemother-
apy, the majority will experience disease recurrence. While re-
treatment with a platinum-based drug is possible for some women
the response rate to current second line chemotherapy is 15–30%
due to the rise of resistance to such drugs requiring the
development of new drugs to treat such tumors [6,9].
The design of new metal-based drugs is often challenged by
physio-chemical properties such as insufficient solubility or
hydrolytic instability making it problematic to control their
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approach to control the cytotoxic responses of new metal-based
compounds is to engage biologically essential transition metals,
such as iron (Fe), manganese (Mn), zinc (Zn), copper (Cu), or
cobalt (Co) of different oxidative states and their reactive
intermediates [4,5]. The current report describes the selective
cytotoxic effects of a novel organometallic complex (Iron(III)-
salophene; Fig. 1A) on platinum-resistant ovarian cancer cells.
Salophenes represent a class of organic compounds defined by
two Schiff’s bases connecting three aromatic moieties. The two
outer aromatic moieties typically feature salisaldehydes and the
central aromatic moiety an o-phenylene-diamine or analog.
Salophenes display potent binding with transition metal elements
and are closely related to salens containing Schiff’s bases that are
constituted of aliphatic diamines. Metallosalens fall into a number
of non-platinum metal compounds such as thiosemicarbazone or
hydrazone pharmacophores with putative anticancer activities
[4,10]. Metallosalophenes have not been studied extensively with
respect to applications in biological systems: previously salophene-
lanthanide complexes were described to selectively bind to neutral
sugars and lipids including lysophosphatidic acid, which serves as a
marker for several pathological conditions including ovarian
cancer [11] and Mn-salophene (EUK178) as well as various Mn-
salens display cyto-protective features in fibroblast cultures via
hydrogen peroxide scavenging [12]. A related compound (cobalt-
3,4-diarylsalen) has been shown to reduce the viability of various
cancer cell lines at rather high concentrations ($20 mM) and it
was suggested that the mode of activity was not linked to oxidative
DNA damage [13]. Based on the present report and further
studies on the selective cytotoxic effects of salophenes when
complexed with transition metals, a patent was filed. This
invention comprises of the synthesis, biological evaluations,
applications, and pharmaceutical compositions of metal-salo-
phenes (MSPs). Furthermore, the invention comprises of use of
MSPs as drugs with therapeutic anti-neoplastic, anti-angiogenic
and anti-cancer activities, and with other properties such as free
radical scavenging. In addition, this invention provides methods to
be applied in chemoprevention of chemical carcinogenesis and
alterations of drug metabolism involving the epoxides or free
oxygen radicals or intermediates.
The objective of the present study was to investigate the
potential of Fe-SP as a biologically active drug in an ovarian
cancer cell model with respect to dose-dependent and specific
effects on viability, morphology, proliferation, and cell-cycle
progression. In addition to describing the selective cytotoxicity of
Fe-SP on platinum-resistant ovarian cancer cells we conducted a
study on the systemic toxicity of Fe-SP when applied in rats as a
model system. The present report suggests that this novel
organometallic compound displays properties as a potential
therapeutic drug and an alternative to platinum reagents in the
treatment of ovarian cancer.
Results
Specific cytotoxic effect of Fe-SP on human platinum-
resistant ovarian cancer cell lines
In an initial approach to analyze the effects of Iron(III)-
salophene (Fe-SP) on ovarian cancer cells we performed a viability
assay employing SKOV-3 and OVCAR-3 (human platinum-
resistant ovarian epithelial adenocarcinoma) cell lines in compar-
ison to HeLa (epithelial cervix adenocarcinoma) or primary lung
(LF) or skin fibroblasts (BJ) (passages 10–13). The cells were treated
for 24 h with various concentrations (0.1–3 mM) of either Fe-SP or
non-complexed salophene (SP) as an additional control to
untreated cells. Treatment with SP did not affect the viability of
any of these cell lines in the range of 100 nM to 3 mM (Fig 2) nor
at concentrations as high as 60 mM (unpublished data). Fe-SP, at
concentrations $3 mM, exerted highly cytotoxic effects on all cell
lines. Remarkably, the response of these cells to Fe-SP was not
only dose-dependent but at concentrations below 3 mM cell type
Figure 1. Synthesis and structure of Iron(III)-salophene. (A) Synthesis of the salophene ligand (SP; from 1,2-phenylenediamine and o-vanillin)
and of the Iron(III)-salophene complex (Fe-SP) (see Materials and Methods). (B) Structural characterization of Fe-SP by X-ray crystallography (see
Table 1.)
doi:10.1371/journal.pone.0002303.g001
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and 1 mM proved to be highly cytotoxic to SKOV-3 and
OVCAR-3 cells, treatment of HeLa cells or primary fibroblasts
with 1 mM Fe-SP did not result in any change of viability. Thus,
Fe-SP depending on the cell line treated, displays selective
cytotoxicity, with a dose-dependent response shown here for two
platinum-resistant ovarian cancer cell lines.
Selective morphological changes and induction of
apoptosis in SKOV-3 ovarian cancer cells after Fe-SP
treatment
To analyze morphological changes of SKOV-3 ovarian cancer
cells and primary fibroblasts (BJ) upon Fe-SP treatment we carried
out light- and fluorescence microscopy after fixation of the cells
and staining of the nuclear chromatin with DAPI. The population
of untreated SKOV-3 or cells treated with 2 mM of non-
complexed SP for 24 h displayed a homogenous morphology
with nuclei lightly and evenly stained by DAPI (Fig. 3A) and
occasional appearances of dividing cells in mitosis (bright blue
staining of chromosomes lined up along the metaphase plate; not
shown here). In contrast, after treatment with 2 mM Fe-SP the
majority of SKOV-3 cells displayed shrinkage, highly condensed
chromatin, and often densely stained nuclear granular bodies
(‘‘apoptotic bodies’’) within fragmented nuclei, (Fig. 3A). Primary
fibroblasts treated with Fe-SP or SP at the same concentration did
not reveal major changes in morphology nor apparent hallmarks
of apoptosis showing the selective response of the ovarian cancer
cell line studied to Fe-SP.
A common method for detecting DNA fragmentation in the
light of cellular apoptotic events is a TUNEL assay, which we
employed after treatment of SKOV-3 with Fe-SP. The assay relies
on the presence of nicks in the DNA of apoptotic and some
necrotic cells, which can be identified by terminal transferase that
will catalyze the addition of labeled dUTP (here: fluorescein).
SKOV-3 cells were treated with either 0.7 or 2 mM Fe-SP for
24 h. To identify cell nuclei, counterstaining with propidium
iodide (Pi), which intercalates in the DNA, was carried out.
TUNEL-positive nuclei were identified by yellow spots resulting
from an overlay of the image with apoptotic stain (FL-dUTP) and
nuclear stain (Pi). As shown (Fig. 3B) no cells before treatment (top
panel), 60% of the population of cells treated with 0.7 mM (middle
panel) and all cells at 2 mM Fe-SP (bottom panel) were TUNEL-
positive cells indicating fragmented DNA.
To define the cellular response of SKOV-3 cells upon Fe-SP
treatment we analyzed the activation of caspases characteristic for
induction of apoptosis as well as the inactivation of PARP-1 by
immunoblotting. Treatment of SKOV-3 cells with 2.5 mM Fe-SP
for 24 h resulted in strong activation/cleavage of caspase-9, -8,
and -3, while PARP-1 was inactivated/cleaved after drug
treatment (Fig. 3C). Treatment with 1.25 mM Fe-SP revealed a
similar result, with some activation of caspase-9, and -3, and
inactivation of PARP-1 while the activation of caspase-8 was as
strong as observed for 2.5 mM Fe-SP. Apparently, the onset of
caspase activation and PARP-1 inactivation in SKOV-3 ovarian
cancer cells by Fe-SP resulted in the morphological hallmarks of
apoptosis observed (Fig. 3A).
Anti-proliferative effect and cell cycle arrest after
treatment of SKOV-3 ovarian cancer cells with Fe-SP
As described in the previous sections Fe-SP is a selective
cytotoxic drug (Fig. 2) which activates apoptotic processes (Fig. 3)
in SKOV-3 ovarian cancer cells. To investigate if Fe-SP exerts
anti-proliferative effects and disturbances of cell cycle progression
we performed a BrdU incorporation assay. Fe-SP treatment for
24 h dose-dependently reduced cell proliferation (Fig. 4) with an
IC50 value of 300 nM. In contrast, non-complexed SP did not
reduce SKOV-3 proliferation significantly even at concentrations
of 3 mM. At the sub-cytotoxic drug concentration of 100 nM Fe-
SP (see viability, Fig 2) BrdU incorporation into the DNA was
reduced by 40% (Fig. 4).
In addition to the cell proliferation assay, cell-cycle analysis of
propidium iodide stained SKOV-3 cells by flow cytometry was
carried out. Fe-SP, in contrast to the non-complexed compound,
revealed an increase in the count of sub-diploidal/2n cells (sub-
G0/G1, Fig. 5A) in a time- and dose-dependent manner (Table 1).
With respect to the cycling cells, Fe-SP causes a time- and dose-
Figure 2. Comparison of the cytotoxic effect of Fe-SP on ovarian cancer and control cell lines. The cytotoxicity of Fe-SP on human
ovarian cancer cells (SKOV-3, OVCAR-3) was compared to the effect on HeLa cells or primary fibroblasts at passages 11 to 13 (LF1, human lung; BJ,
human foreskin). The cells were treated for a total of 24 h with various concentrations (0.1–3 mM) of Fe-SP or non-complexed SP (Ctr). The MTS
viability assay was carried out as described (Materials and Methods). Experiments were performed in triplicates; data are expressed as the mean of the
triplicate determinations (X6SD) of a representative experiment in % cell viability of untreated cells [=100%].
doi:10.1371/journal.pone.0002303.g002
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cells in G0/G1 phase: Untreated cells or SKOV-3 treated with
non-complexed SP in this non-synchronous population while
cultured in vitro are ,71–75% in G0/G1 and ,21–24% in S
phase (Fig. 5B, Table 1). Treatment with Fe-SP at increasing
concentrations (0.4, 0.8, 1.6 mM) for 24 or 48 h caused an increase
of cells in S-phase peaking at 75% (1.6 mM/24 h) and 87%
(1.6 mM/48 h) of the total population (Fig. 5B, Table 1).
Accordingly, the number of cells in G0/G1 decreases to 25%
(1.6 mM/24 h) and 13% (1.6 mM/48 h) of the total population,
while at this Fe-SP concentration no more cells in G2/M can be
detected. At a concentration of 0.8 mM Fe-SP for 24 h and 48 h
an increase of cells in G2/M (23%/24 h; 16%/48 h) over the base
level (3%/24 h, 9%/ 48 h) can be observed which indicates a
delay of this phase along with a developing arrest of cells in S-
phase.
Cytotoxicity of Fe-SP in rats as a model system
To investigate if Fe-SP causes systemic toxicity in vivo we chose
rats as a model system. In preliminary the chemotherapeutic
Figure 3. Morphology changes, DNA fragmentation and Caspase activation of ovarian cancer cells and after Fe-SP treatment. (A)
Morphological appearance/DAPI staining. Ovarian cancer cells (SKOV-3) or primary fibroblasts (BJ) were treated for 24 h with Fe-SP or non-
complexed SP (Ctr.) at a concentration of 2 mM before microscopic analysis by phase contrast (PC) or fluorescence analysis after chromatin staining
(DAPI) as described (Materials and Methods). Images obtained from a representative experiment are shown. Bar=10 mm. (B) Analysis of DNA
Fragmentation in a TUNEL Assay. SKOV-3 cells were treated with Fe-SP (0, 0.7, 2 mM) for 24 h. A TUNEL assay was carried out by co-staining with
fluorescein-12-dUTP (labeling of DNA nicks in apoptotic cells) and of chromatin with propidium iodide (Materials and Methods). Co-staining of
untreated SKOV-3 cells before fixation and permeabilization served as negative control (insert top panel). During fluorescent microscopy,
representative images were taken, apoptotic stain (green) and nuclear stain (red) overlaid. TUNEL positive nuclei due to DNA fragmentation appear as
yellow areas. Bar=10 mM. (C) Western Blot Analysis of Caspase activation. SKOV-3 cells were treated with Fe-SP (0, 1.25 mM, 2.5 mM) for 24 h.
PAGE and Western blot analysis of cell lysates was carried out. Activated Caspase-3, -8, -9, and inactivated PARP-1 was visualized by immunoblotting
using primary antibodies solely recognizing cleaved fragments, not full length pro-forms, of these proteins in combination with a chemiluminescence
detection system as described in (Materials and Methods). A representative experiment is shown. As an internal standard for equal loading (50 mg
total cell protein/lane) blots were probed with an anti-b-Actin antibody.
doi:10.1371/journal.pone.0002303.g003
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were determined to be #1 mg/kg body weight (Lange et al. in
preparation). In these trial studies rat ovarian cancer cells (NUTU-
19) were intra-peritoneally (IP) injected into rats and 3 weeks after
development of tumors (to mimic the situation following
cytoreductive surgery) animals were treated daily with Fe-SP via
IP injections. Duration of treatment lasted 12 days and was based
on tumor burden in the control animals. Animals were monitored
for any discomfort and pain per IACUC protocols. While control
animals showed a consistently elevated amount of hemorrhagic
ascites, the Fe-SP (1 mg/mL) treated animals displayed signifi-
cantly less hemorrhagic ascites volume, and less omental tumor
weight. Moreover, in this preliminary treatment trial, we observed
a complete response in 40% of treated animals (10 rats treated).
Consequently, we carried out 28-day chronic toxicity studies
(OECD guidelines for the testing of chemicals (Section-4, No.-407))
in albino rats with Fe-SP concentrations ranging from 0.25 mg/Kg
to 4 mg/Kg body weight. This study was designed to investigate the
toxicological effects of repeated IP administration of Fe-SP (in
DMSO:distilled water at the ratio of 1:4on 5 days/week for a period
of 28 days). Animals in a low dose group (0.25 mg/Kg body weight),
intermediate dose group (1.0 mg/Kg body weight), and high dose
group (4.0 mg/Kg body weight) did not reveal any pathological
changesascomparedtothecontrolgroupofanimals.Nomortalityor
toxic symptoms were observed in test and control groups of animals
except ruffled fur in the high dose group. No significant differences
were observed in the body weight gain/loss pattern, organ weight,
hematological or biochemical parameters (see Material and
Methods) of all the test groups when compared to the control group.
All parameters fellwithin the accepted limits of normal variations for
albino rats.Microscopic examination ofhistopathologicalslides from
the low, intermediate, and high dose groups did not show any
significant changes except mild degeneration of hepatocytes in three
animals(atthehighdose)andpulmonarymononuclearcellinfiltrates
in two animals (high dose).
Discussion
A low 5-year overall survival rate of only 53% for woman
suffering from ovarian cancer is related to the development of
resistance of tumor cells to standard chemotherapeutic agents,
most notably platinum analogs and therefore new anti-cancer
drugs need to be developed [6,7,8]. For the present report we
chose to study the potential of a novel organometallic complex,
Iron(III)-salophene (Fe-SP) as a candidate agent for treatment of
ovarian cancer. For purposes of clarification, it is mentioned that
the term salophene, more than a century ago, has been applied to
4-acetamidophenyl salicylate, an analgesic, and antipyretic drug
manufactured since the early 1900’s by Bayer Pharmaceutical
Products (Leverkusen, Germany) [14] and is not related to
‘‘Salophen’’ discovered as a superoxide scavenger in E. coli when
complexed with manganese(III) [15] that resembles the organo-
metallic compound studied in the present report.
To date no research on the specific effects of salophenes on the
viability of cancer cells has been published. In an earlier study on
the cytotoxic effects of bicyclic aryl thiazolines on various human
cancer cell lines, we determined the range of the colorimetric cell-
viability assay used by employing Iron(III)-salophene (not related
to thiazolines) at 60 mM as a negative control [16]. Subsequent
comparative studies on the effect of transition-metal salophenes
(Zn(II)-, Mn(II)-, Cu(II)-, Co(III), Fe(III)-SP) and non-complexed
salophene (SP) at lower concentrations revealed that below a
concentration of 10 mM only Fe(III)-SP displayed significant
cytotoxic effects in various cancer cell lines (Lange et al., in
preparation). To test the selective cytotoxic potential of Fe-SP on
ovarian cancer cells, we chose two cell lines that are multi-drug
resistant alongside with primary lung or skin fibroblasts cell lines.
OVCAR-3 cells (ovarian epithelial adenocarcinoma) are resistant
to clinically relevant concentrations of adriamycin, melphalan and
cisplatin. SKOV-3 cells (ovarian adenocarcinoma) are resistant to
several cytotoxic drugs including Cisplatin and Adriamycin (see
ATCC, Manassas, VA; www.atcc.org). Similar to the these two
ovarian cancer cell lines, the control cells used in the present
report, primary fibroblast at early passages and HeLa cells, possess
a high metabolism and growth rate. We show here that Fe-SP
displayed selective and dose-dependent cytotoxicity against
SKOV-3 and OVCAR-3 cells at concentrations between 100
nM and 1 mM, while the viability of HeLa cells (epithelial cervix
adenocarcinoma) or primary lung- or skin- fibroblasts (at passages
10–13) at these concentrations was not affected. The relative
resistance of the three control cell lines to Fe-SP supported the idea
of testing this compound an in vivo ovarian animal cancer model.
Non-complexed salophene did not affect the viability of either cell
line even at concentrations of up to 60 mM nor did 60 mM Fe(III)
alone [ferric chloride added] or ferric chloride in combination
with non-complexed salophene added to the cell culture media
[Lange et al., in preparation] indirectly confirming the stability of
the complex and, thus, specific cytotoxic action under cell culture
conditions.
Given the present state of research in the field of organometallic
compounds such as salophenes or salens (related compound, see
introduction), we can only speculate from limited sources about
the possible mechanism(s) of cytotoxic action of Fe-SP. A
remarkable feature of salens, not yet examined for salophenes, is
their affinity to a variety of aromatic neutral molecules such as
pyridine, pyridine N-oxide, isoquinoline and benzylamine [17,18].
Salens when complexed with transition metals act as artificial
nucleases. Their reactivity in plasmid DNA cleavage assays can be
controlled by conjugation or by the type and charge of the central
metal ion core [18,19,20]. For example, Ni(II)- or Mn(II)-salens
were found to efficiently induce DNA strand scission but not
Cr(II)- or Cu(II)- [18,20] or Fe(II)-salens unless additional
hydroxyl groups facilitate their oxidation to Cu(III) or Fe(III)
species [21]. It has been postulated that Fe-salen in cooperation
Figure 4. Fe-SP inhibits proliferation of ovarian cancer cells.
Ovarian cancer cells (SKOV-3) were treated with various concentrations
(0.1–10 mM) of Fe-SP or non-complexed SP (Ctr.) for 24 h. A colorimetric
assay (based on BrdU incorporation detected by a BrdU-antibody
peroxidase conjugate) was carried out as described (Materials and
Methods). The color intensity at 450 nM correlates directly to the
amount of BrdU incorporated into the DNA, which in turn represents
proliferation. Experiments were performed in triplicates; data are
expressed as the mean of the triplicate determinations (X6SD) in %
of absorbance by triplicate samples of untreated cells [=100%].
doi:10.1371/journal.pone.0002303.g004
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species to produce free hydroxy radicals responsible for DNA
cleavage [21]. However, the DNA cleavage activity of Fe(III)-salen
is higher than of Fe(II)-salen suggesting that the increased water-
solubility and charge of the Fe(III) ion is dominating the cleavage
potential of the structure [22] which likely applies to iron(III)-
salophene, as well. In addition, the authors linked the DNA
cleavage activity by Fe(III)-salen in vitro to the observation that this
compound caused nuclear fragmentation and induction of
apoptosis (via mitochondrial pathway/cytochrome c release) in
HEK293 cells at a concentration of 50 mM [22].
While the mechanism(s) of action of salens or Fe-SP on cells in
culture or in vivo remains to be investigated, selective morpholog-
ical changes of cancer cell lines and induction of apoptosis after
drug treatment in vitro are a first indicator for potential selective
effects on tumor metastasis and cell physiology in vivo. The present
study shows that Fe-SP at concentrations of 2 mM in SKOV-3
ovarian cancer cells but not in primary fibroblasts caused nuclear
fragmentation, chromatin condensation, DNA fragmentation
which are all classic hallmarks of apoptosis [23]. Western blotting
confirmed the activation of effector caspase-3 and inactivation of
PARP-1 (involved in DNA repair) [24] during the execution of
apoptosis in SKOV-3 cells following Fe-SP treatment. Moreover,
it was apparent that Fe-SP induced both major signaling pathways
(intrinsic, extrinsic) described for programmed cell death [25,26]. We
observed strong cleavage/activation of initiator caspase-8, typical
for the involvement of the extrinsic apoptotic pathway [27,28],
upon Fe-SP treatment of SKOV-3 cells. The intrinsic pathway
Figure 5. Fe-SP causes S-Phase cell cycle arrest in ovarian cancer cells. Ovarian cancer cells (SKOV-3) were treated with 0, 0.4, 0.8 and 1.6 mM
Fe-SP or SP (Ctr.) for 24 or 48 h. Cell cycle analysis by FACS based on propidium-iodide intercalation into the cellular chromatin was carried out as
described (Materials and Methods). Data are presented as (A) relative fluorescence intensity in a 2-dimensional FACS profile (ModFit LT software;
black lines=data line and model fit line of entire population; shaded areas=model components/subpopulations of G0/G1, S, G2/M, apoptotic cells),
example shown for 48 h treatment with 0.8 mM compound, or as (B) comprehensive bar diagram of all data. Standardized gating was used for all
samples. Ten thousand events were analyzed for each sample.
doi:10.1371/journal.pone.0002303.g005
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damage or growth factor deprivation and is initiated by
mitochondrial damage. It results in the mitochondrial release of
cytochrome C which activates initiator caspase-9 [28,29] and was
shown to contribute to cell death of HEK293 (human kidney cell
line) upon Fe(III)-salen treatment [22] and also in the present
study for SKOV-3 cells upon Fe(III)-salophene treatment. To
date, no other studies describing the morphology or apoptotic
signaling of any cell lines after treatment with compounds
belonging to the class of iron-salens or -salophenes have been
published.
Similarly, no publications examining the change in cell cycle
progression following treatment with either a salen or salophene
metallocomplex exist. While one publication observed a change in
viability andmorphology of skinfibroblasts inculture after treatment
with a Cr(III)-salen complex at high concentrations of 50 mM, the
following cell cycle studies were only conducted with a ethylendia-
mine-Cr(III)-chloride of higher cytotoxicity [30]. We show here that
Fe-SP dose-dependently reduced the proliferation of SKOV-3
ovarian cancer cells (IC50 at 300 nM). Even at the sub-cytotoxic
concentrations (100 nM Fe-SP) BrdU incorporation into the DNA
was reduced indicating that Fe-SP exerts effects as an anti-
proliferative and, thus, a potential anti-cancer agent. Additional
cell-cycle analysis of SKOV-3 after Fe-SP treatment, as already
indicated in the TUNEL assay, revealed an increase in the sub-
diploidal population which represents cells with significant DNA
damage, indicating a late apoptotic stage. With respect to the cycling
cells, Fe-SP at 1.6 mM caused a full arrest of SKOV-3 in S-phase
along with decrease of cells in G0/G1 and a total loss of cells in G2/
M. Apparently, Fe-SP treatment affected cell-cycle checkpoints in S-
phase causing a dose and time-dependent reduction of cell-cycle
progression. To date, this is the first report on the regulation of the
cycle of any cell line by treatment with either metallosalen or
metallosalophene compounds. Furthermore, only few data on the
effect of transition metal complexes in general on the cell cycle exist,
such as the arrest of a neuroblastoma cell line in G1-phase when
treated with an isatin-schiff base copper(II) complex [31].
Even though not the objective of this report, further studies
could analyze the effects of Fe-SP on cell-cycle checkpoints in
synchronized SKOV-3 cultures and other cancer and
non-transformed cell lines. Targeting such checkpoints has been
suggested as an alternative approach to anti-cancer therapies
[32,33]. Regulators of the cell-cycle machinery are frequently
altered in human cancer and apparently transformed cells can be
more sensitive to the cyclin-dependent kinases (CDK) inhibition
[34,35]. With respect to S-phase events both mouse models and
studies on cancer-derived cells revealed that accumulation of
cyclin D1/CDK4 complexes triggers DNA re-replication [36]
and, thus, could be specifically targeted in cancer cells. As one
example, Guggulsterone, a plant-derived drug, caused cell-cycle
arrest in S-phase by the suppression of cyclin D1 and cdc2 and
increased cyclin-dependent kinase inhibitor p21 and p27 expres-
sion in a wide variety of human tumor cell types [37]. Based on the
specific arrest of SKOV-3 cells by Fe-SP in S-phase observed in
the present study, in future studies we will analyze the effects of
this novel organometallic compound and potential cancer
therapeutic on specific cell-cycle regulators (CDK’s, cyclins) and
replication-start and -progression signals of the S-phase [38,39] in
platinum-resistant ovarian cancer cells.
To set the stage for further investigation of Fe-SP as a potential
therapeutic drug in addition to these in vitro studies we conducted a
standardized study (28-day chronic toxicity) on the systemic
toxicity of Fe-SP when applied in rats as a model system. When
intra-peritoneally administered, Fe-SP did not show any systemic
toxicity at even four times the concentration (4 mg/Kg body
weight) that in our preliminary treatment trials were determined to
be chemotherapeutic relevant doses (#1 mg/Kg body weight) of
Fe-SP in a rat ovarian cancer cell model. The present report
suggests that Fe-SP is a potent growth-suppressing agent in vitro for
cell lines derived from ovarian cancer and a potential therapeutic
drug to treat such tumors in vivo.
Materials and Methods
Animal experiments were carried out in the animal facilities of
Rhode Island Hospital (RIH), RI USA with strict adherence to the
guidelines of the Animal Welfare Committee of RIH and Women
& Infants Hospital and at the Shriram Institute for Industrial
Research, Delhi, India in accordance with the guidelines set by the
Laboratory Animal Safety Committee of the Shriram Institute.
Synthesis of Iron(III)-salophene
The synthesis of the salophene ligand (SP, Fig. 1) followed a
previously reported procedure [40]. 1,2-phenylenediamine
(1.24 g, 11.5 mmol) was added to a solution of o-vanillin (3.5 g,
23 mmol) in anhydrous ethanol (20 mL) and the yellowish solution
stirred and refluxed for 2 h. The reddish suspension was filtered
and re-crystallized with boiling ethanol and the resultant reddish
needles collected and dried (2.8 g SP, 65% yield). The Iron(III)-
salophene complex (Fe-SP, Fig. 1) was prepared as follows: SP
(550 mg, 1.46 mmol) dissolved in acetone (44 mL) was carefully
combined with ferric chloride hexahydrate (394.9 mg, 1.46 mmol)
dissolved in acetone (5.5mL). The resultant microcrystalline solid
that grew in solution was filtered, washed thoroughly with acetone,
and dried to obtain the Fe-SP complex (244.6 mg, 35% yield). Fe-
SP was dissolved in DMSO (dimethyl sulfoxide) for experiments in
tissue culture and characterized by HPLC and X-ray crystallog-
raphy (Table 2) with a high resolution x-ray diffraction system
(Bruker SMART diffractometer using SHELXTL-97 software;
Bruker AXS Inc., Madison, WI).
Cell culture
SKOV-3 (human ovarian adenocarcinoma), OVCAR-3 (hu-
man ovarian epithelial adenocarcinoma), HeLa (human epithelial
Table 1. Cell Cycle analysis of SKOV-3 after Fe-SP treatment.
Fe-SP SP Ctr.
Sub- Sub-
G0/G1 S G2/M G0/G1 G0/G1 S G2/M G0/G1
[%] [%] [%] [%] [%] [%] [%] [%]
No Drug 75.0 22.1 2.9 1.2 72.5 24.0 3.5 1.2
24 h 0.4 mM 73.8 19.4 6.9 7.2 73.8 20.9 5.3 0.8
0.8 mM 44.7 28.0 13.9 5.8 71.2 22.9 5.9 3.9
1.6 mM 24.6 75.4 0 16.7 72.2 21.7 6.1 0.5
No Drug 74.4 16.5 9.0 0.3 71.6 17.8 10.7 0.3
48 h 0.4 mM 65.5 22.3 12.3 9.8 68.9 19.8 11.3 0.7
0.8 mM 43.3 40.9 16.3 17.3 70.0 18.4 11.6 1.5
1.6 mM 12.9 87.1 0 15.8 73.0 16.4 10.6 1.0
Cell cycle analysis was carried out as described (Materials and Methods). SKOV-3
cells were treated with 0, 0.4, 0.8 and 1.6 mM Fe-SP or SP (Ctr.) for 24 or 48 h.
Data were obtained by FACS analysis based on propidium-iodide intercalation
into cellular chromatin.
doi:10.1371/journal.pone.0002303.t001
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BJ (primary human fore skin fibroblasts) cell lines were obtained
from American Type Culture Collection (Manassas, VA). Cells
were grown in T75 cell culture flasks (Corning, New York, NY) to a
confluency of ,80% in complete Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with sodium ascorbate (50 mg/
ml), glutamine (300 mg/mL), penicillin (400 mg/mL), streptomycin
(50 mg/mL) and 10% fetal calf serum (FCS) on in a humidified
atmosphere of 5% CO2 and 95% air at 37uC. For all assays cells,
after seeding, were allowed to attach overnight in complete medium
before treatment as indicated in complete medium.
Cell viability assay
Viability of cell lines before and after drug treatment was
determined by the CellTiter 96H AQueous One Solution Assay
(Promega Corp, Madison, WI) following the manufacturer’s
recommendations. This colorimetric assay is based on the ability
of mitochondria to reduce a substrate [MTS, 3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium] into a soluble formazan product quantified by measuring
the absorbance at 490 nm. The resulting OD is directly
proportional to the number of living cells [41]. Briefly, cells
(5610
3/well) were plated into 96 well flat bottom plates (Corning,
Inc., Corning, NY) before treatment with various drugs or vehicle
(DMSO) as indicated. Following incubation at 37uC in a cell
culture incubator for 20h MTS reagent was added at a 1:10
dilution to the medium. The samples were incubated for an
additional 4 h before absorbance was measured at 490 nm in an
ELISA plate reader (Thermo Labsystems, Waltham, MA).
Experiments were performed in triplicates; data are expressed as
the mean of the triplicate determinations (X6SD) of a
representative experiment in % of absorbance by samples with
untreated cells [=100%].
Morphological Studies
Cells were seeded (1610
4/chamber) into a Lab-Tek Chamber-
Slide System (Nalge Nunc., Naperville, IL) and treated for 24 h
with 2 mM Fe-SP or SP as a negative control alongside with non-
treated cells. Following two wash-steps in PBS the cells were fixed
in PBS, 2% PFA, 0.2% Triton X for 20 min at RT and stained for
10 min with 200 ng/mL 49-6-Diamidino-2-Phenylindole (DAPI)
in PBS before mounting. Representative images were taken with
an inverted microscope (Nikon Eclipse TE2000-E, CCD camera)
and 20x objective.
Table 2. Crystal data and structure refinement of Fe-SP (crystallized in acetone)
Identification code kko133cmsad
Empirical formula C25H26ClFeN2O6
Formula weight 541.78
Temperature 90(2) K
Wavelength 0.71073 D
Crystal system Monoclinic
Space group P2(1)/n
Unit cell dimensions a=10.2706(12) Da =90u
b=13.9248(17) Da =101.104(2)u
c=16.985(2) Da =90u
Volume 2383.7(5) D
3
Z 4
Density (calculated) 1.510 Mg/m
3
Absorption coefficient 0.790 mm
21
F(000) 1124
Crystal size 0.3060.3060.08 mm
3
Theta range for data collection 1.91 to 28.31u.
Index ranges 213,=h,=13, 218,=k,=18,222,=l,=22
Reflections collected 20658
Independent reflections 5769 [R(int)=0.0389]
Completeness to theta=28.31u 97.4%
Absorption correction Empirical
Max. and min. transmission 0.9 and 0.8
Refinement method Full-matrix least-squares on F
2
Data/restraints/parameters 5769/0/322
Goodness-of-fit on F
2 1.046
Final R indices [I.2sigma(I)] R1=0.0420, wR2=0.0997
R indices (all data) R1=0.0536, wR2=0.1065
Largest diff. peak and hole 0.710 and 20.311 eD
23
doi:10.1371/journal.pone.0002303.t002
Cytotoxicity of Iron-Salophene
PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2303TUNEL Assay
DNA fragmentation was detected using the DeadEndTM
Fluorometric TUNEL System assay (Promega, Madison, WI)
according to the manufacturer’s recommendations. Cells (5610
3/
well) were plated into 96 well flat bottom plates (Corning, Inc.,
Corning, NY), treated with 0.7 or 2 mM Fe-SP and the assay
carried out as described previously [42]. Fluorescence of apoptotic
cells (green; labeling of DNA nicks by fluorescein-12-dUTP) and of
chromatin (red; staining of chromatin with propidium iodide) was
detected by fluorescence microscopy with an inverted microscope
(Nikon Eclipse TE2000-E) and a 10x objective. Four randomly
chosen microscopic fields were captured.
Western blot analysis
Cells were seeded into 100 mm
2 tissueculture dishes (5610
5 cells/
dish), and treated with 1.25 or 2.5 mM Fe-SP for 24 h. Preparation
of cell lysates, PAGE and immunoblotting was carried out as
described previously [43]. Primary antibodies purchased from Cell
Signaling Technology (Beverly, MA) against cleaved Caspase-3
(#9661), cleaved caspase-8 (#9748), cleaved caspase-9 (#9501),
cleaved PARP-1 (#9541), b-actin (#1501) were used. Antibodies
were diluted 1:1000 in 5% BSA/PBST; incubation and wash steps
carried out as in [43]. The antibody specific for cleaved caspase-3
detects the large fragment (17/19 kD) of activated caspase-3
(cleavage adjacent to Asp175) and does not recognize the full length
protein. The antibody specific for cleaved caspase-8detects the small
fragment of caspase-8 (cleavage at aspartic acid384) and does not
cross-react with the full length protein. The antibody specific for
cleaved caspase-9 detects the large fragment of caspase-9 (cleaved at
Asp330) and does not recognize full length protein. The antibody
specific for cleaved PARP detects the large fragment of PARP-
1(produced by caspase cleavage at Asp214) and does not recognize
full length PARP-1 or other PARP isoforms. The bands were
visualized using horseradish peroxidase-conjugated secondary anti-
bodies (Amersham-Pharmacia Biotech, Piscataway, NJ), followed by
enhanced chemiluminescence (Upstate, Waltham, MA) and docu-
mented by autoradiography (F-Bx810 Film, Phenix, Hayward, CA).
Cell Proliferation Assay
Proliferation of various cell lines was determined by a BrdU (5-
bromo-29-deoxyuridine) incorporation assay (Roche Applied
Science, Indianapolis, IN) according to the manufacturer’s
recommendations. Briefly, cells (5610
3/well) were plated into 96
well flat bottom plates (Corning, Inc., Corning, NY) before
treatment as indicated (result section) for 18 h in FCS free media.
BrdU (10 mM final concentration) was added to the cells grown for
further 6 h. After washing cells were fixed and incubated for 2 h at
37uC with an anti-BrdU antibody-peroxidase conjugate. Immu-
nocomplexes were detected by addition of a tetramethyl-benzidine
(TMB) substrate solution according to the manufacturer’s
recommendations. The reaction was stopped by adding 50 mL
of 1M sulfuric acid, and the absorbance was measured with an
ELISA plate reader (Thermo Labsystems, Waltham, MA) at
450nm. In this assay, the color intensity correlates directly to the
amount of BrdU incorporated into the DNA, which in turn
represents proliferation. Experiments were performed in tripli-
cates; data are expressed as the mean of the triplicate
determinations (X6SD) of a representative experiment in % of
absorbance by samples with untreated cells [=100%].
Cell Cycle Analysis
Cell cycle analysis and quantification of apoptosis was carried
out by flow cytometry. Cells were seeded into 100 mm
2 tissue
culture dishes (7.5610
5 cells/dish) and treated with Fe-SP as
indicated (result section) At the end of the incubation period
detached cells were collected in 15 mL polypropylene centrifuge
tubes along with the medium; culture dishes were washed once
with PBS. Adherent cells were scraped off and combined in the
same tube. After centrifugation (250 g, 5 min), cells were fixed and
permeabilized with ice-cold 70% ethanol for 30 minutes, followed
by incubation with 50 mg/mL of propidium iodide and 100 mg/
mL of RNase for 30 min at 37uC in the dark. Data was acquired
on a BD FACSort flow cytometer using CellQuest software (BD
Immunocytometry Systems, San Jose, CA) and analyzed using
ModFit LT software (Verity Software House, Inc., Topsham,
ME). Ten thousand events were analyzed for each sample.
Appropriate gating was used to select the single cell population
and used on all samples, ensuring that the measurements were
made on a standardized cell population.
In vivo toxicity study
Sample preparation. Working solutions of Fe-SP from a
stock solution of 10 mM in 100% DMSO were prepared in vehicle
(DMSO:distilled water at a ratio of 1:4) for repeated
intraperitoneal administration of rats (0.25 mg/Kg, 1 mg/Kg,
and 4 mg/Kg body weight).
Animals. Thirty healthy adult male and thirty healthy adult
female rats (Wistar-albino rats, 6–8 weeks of age and weighing
160–180 g, purchased from the laboratory animal facility of the
Shriram Institute, Delhi, India) were acclimatized for 7 days and
animals were caged in a group of 5 according to sex in
polypropylene cages fitted with wire mesh tops and having
sterilized paddy husk bedding. The rats were then randomized and
assigned to 6 groups of 5 male and 5 female rats each and
identified by cage tag having name of test substance and details of
group, dose level and sex.
Administration. The first group, i.e. the control group, was
given vehicle only. The second, third, and fourth groups of
animals were administered 0.25, 1.0, or 4.0 mg/Kg body weight
of Fe-SP in vehicle. The fifth and sixth groups were assigned as the
satellite control and satellite high dose group (4.0 mg/Kg body
weight) and treated with vehicle only (control) or Fe-SP in vehicle.
The rats were observed daily for behavior, appearance, and
toxicological sign and symptoms.
Body weight. Recorded individually before treatment and at
weekly intervals, thereafter group mean body weights were
calculated.
Signs/symptoms. Macroscopic evaluation, recorded daily
in terms of clinical manifestation, if any.
Termination of the study. The following clinical laboratory
determinations were made in all the animals of each group after
termination of the experiment. Feed was withdrawn overnight
prior to the collection of samples. Four to 6 ml of blood was
withdrawn by cardiac puncture under light nembutol anesthesia
prior to sacrifice. The following hematological measurements were
performed on control and treated groups of animals (using a Baker
Hematology system 9120+): WBC, RBC, Hemoglobin (Hb),
Hematocrit (Hct), Platelets, Neutrophils (N), Lymphocytes (L),
Basophils (B), Monocyte (M), Eosinophils (E), and Prothrombin
time. The following serum chemistries were also performed on
control and treated rats using Boehringer Mannheim diagnostic
kits: Blood Glucose, Blood urea nitrogen (BUN), Total protein
(TP), Albumin, Serum glutamic oxalo acetate transaminase
(SGOT), Serum glutamic pyruvic transaminase (SGPT), Serum
alkaline phosphatase (SAP), and Cholesterol.
Post mortem evaluation. No mortality during the study in
treatment or control groups was observed. After 28 days the
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kidneys, liver, lungs, spleen, adrenals, testis, ovaries, uterus.
Microscopic histopathological examination of the tissues listed
above as well as of stomach and intestine were carried out. The
student’s t-test was used for the biostatistical interpretation of the
animal data.
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